|
|
Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer's Disease
Sources News Release
http://www.sources.com/Releases/NR1208.htm
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 21/03/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The
Abstract: ANAVEX 2-73 trial to be initiated immediately in Germany
Hoboken, NJ – March 15, 2011 -- Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase...
To read the full release go to http://www.sources.com/Releases/NR1208.htm
Topics
|
AlterLinks
c/o Sources
© 2025.
|
|
|
|
